Siglec15 facilitates the progression of non-small cell lung cancer and is correlated with spinal metastasis

Haifeng Liang; Qing Chen; Zhichao Hu; Lei Zhou; Qingbing Meng; Taiwei Zhang; Ben Wang; Yuxiang Ge; Shunyi Lu; Wang Ding; Xiaogang Zhou; Xilei Li; Hong Lin; Libo Jiang; Jian Dong

doi:10.21037/atm-22-764

Siglec15 facilitates the progression of non-small cell lung cancer and is correlated with spinal metastasis

Ann Transl Med. 2022 Mar;10(6):281. doi: 10.21037/atm-22-764.

Authors

Haifeng Liang^#^{1

2}, Qing Chen^#^{1

2}, Zhichao Hu^#^{1

2}, Lei Zhou^{1

2}, Qingbing Meng^{1

2}, Taiwei Zhang^{1

2}, Ben Wang^{1

2}, Yuxiang Ge³, Shunyi Lu¹, Wang Ding³, Xiaogang Zhou^{1

2}, Xilei Li^{1

2}, Hong Lin^{1

2}, Libo Jiang^{1

2}, Jian Dong^{1

2

4}

Affiliations

¹ Department of Orthopaedic Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
² Cancer Center, Zhongshan Hospital, Fudan University, Shanghai, China.
³ Department of Orthopedics Surgery, Minhang Hospital, Fudan University, Shanghai, China.
⁴ Department of Orthopaedic Surgery, Zhongshan Hospital Wusong Branch, Fudan University, Shanghai, China.

^# Contributed equally.

Abstract

Background: Non-small cell lung cancer (NSCLC) frequently metastasizes to bone, leading to poor prognosis. Siglec15 has been identified as a newly discovered immune checkpoint and exists in a variety of tumors. However, the expression and function of Siglec15 in NSCLC and bone metastasis remains largely unclear.

Methods: Siglec15 expression in NSCLC and the correlation between Siglec15 expression and the clinicopathological factors of patients with NSCLC were analyzed using The Cancer Genome Atlas (TCGA) dataset. Correlation analysis between Siglec15 and bone metastasis-related genes expression was based on the Molecular Signatures Database (MSigDB). Western blotting and immunohistochemistry were applied to detect Siglec15 expression in NSCLC and spinal metastasis. Human A549 and mouse CMT167 cells were transfected with Siglec15 siRNA to investigate its biological functions in NSCLC proliferation, migration, and invasion. The immune-related signaling pathways and correlations between Siglec15 and tumor-infiltrating immune cells and different immune checkpoints in the NSCLC tumor microenvironment (TME) were analyzed using Estimating Relative Subsets of RNA Transcripts (CIBERSORT) and gene set enrichment analysis (GSEA). To demonstrate Siglec15 in NSCLC cell-mediated T cell suppression and investigate the potential mechanism of Siglec15 silencing in antitumor immunity, we used a T cell killing assay in vitro and the high‑throughput sequencing approach.

Results: Siglec15 expression was positively associated with the tumor stage and lymph node metastasis, and was markedly up-regulated in NSCLC bone metastasis. Functionally, Siglec15 knockdown inhibited the proliferation, migration, and invasion of NSCLC cells (A549 and CMT167 cell lines). A total of eight kinds of tumor-infiltrating immune cells were found to have a strong association with the Siglec15 expression in NSCLC cases. The expression of previously discovered immune checkpoints was higher in the high Siglec15 expression NSCLC group. Furthermore, an in vitro T cell killing assay showed that the down-regulation of Siglec15 in tumor cells could enhance the antitumor immune responses of CD8⁺ T cells. High‑throughput sequencing revealed the potential molecular mechanisms underlying the Siglec15-mediated immunosuppression effect of tumor cells on immune cells.

Conclusions: Siglec15 may be involved in the pathogenesis of spinal metastasis in NSCLC and provide a new potential therapeutic target for the treatment of NSCLC and bone metastasis.

Keywords: Non-small cell lung cancer (NSCLC); Siglec15; bone metastasis; immunosuppression; tumor progression.